Prion diseases: Current understanding of epidemiology and pathogenesis, and therapeutic advances

CNS Drugs

Volumn 20, Issue 1, 2006, Pages 15-28

  Caramelli, Maria ^a   Ru, Giuseppe ^a   Acutis, Pierluigi ^a   Forloni, Gianluigi ^b  

^a LIGURIA E VALLE D AOSTA   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

4' IODOESORUBICIN; ACRIDINE; MEPACRINE; PHENOTHIAZINE; TETRACYCLINE;

BOVINE SPONGIFORM ENCEPHALOPATHY; CLINICAL TRIAL; CREUTZFELDT JAKOB DISEASE; DISEASE ASSOCIATION; GENOTYPE; GEOGRAPHY; HUMAN; INCIDENCE; MEDICAL LITERATURE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RETICULOENDOTHELIAL SYSTEM; REVIEW; RISK FACTOR; STATISTICAL ANALYSIS;

ANIMALS; CATTLE; CREUTZFELDT-JAKOB SYNDROME; ENCEPHALOPATHY, BOVINE SPONGIFORM; HUMANS; PRION DISEASES; RISK FACTORS;

EID: 30344443107     PISSN: 11727047     EISSN: 11727047     Source Type: Journal    
DOI: 10.2165/00023210-200620010-00002     Document Type: Review

References (130)

1. Collins SJ, Lawson VA, Masters CL. Transmissible spongiform encephalopathies. Lancet 2004; 363: 51-61
2. Chisea R, Piccardo P, Quaglio E, et al. Molecular distinction between pathogenic and infectious properties of the prion protein. J Virol 2003; 77: 7611-22
3. Prusiner SB. Prion diseases and the BSE crisis. Science 1997; 278: 245-51
4. Wells GAH, Scott AC, Johnson CT, et al. A novel progressive spongiform encephalopathy in cattle. Vet Rec 1987; 121: 419-20
5. Will RG, Ironside JW, Zeidler M, et al. A new variant of Creutzfeldt-Jakob disease in the UK. Lancet 1996; 347: 921-5
6. Bruce ME, Will RG, Ironside JW, et al. Transmissions to mice indicate that 'new variant' CJD is caused by the BSE agent. Nature 1997; 389: 498-501
7. Hill AF, Desbruslais M, Joiner S, et al. The same prion strain causes vCJD and BSE. Nature 1997; 389: 448-50
8. Collinge J, Sidle KC, Meads J, et al. Molecular analysis of prion strain variation and the aetiology of 'new variant' CJD. Nature 1996; 383: 685-90
9. Foster JD, Hope J, Fraser H. Transmission of bovine spongiform encephalopathy to sheep and goats. Vet Rec 1993; 133: 339-41
10. Forloni G. Immune system contributing to prion diseases. Drug Discov Today 2004; 1: 351-6
11. Anderson RM, Donnelly CA, Ferguson NM, et al. Transmission dynamics and epidemiology of BSE in British cattle. Nature 1996; 382: 779-87
12. Stevenson MA, Wilesmith JW, Ryan JB, et al. Temporal aspects of the epidemic of bovine spongiform encephalopathy in Great Britain: individual animal-associated risk factors for the disease. Vet Rec 2000; 147: 349-54
13. Beisel CE, Morens DM. Variant Creutzfeldt-Jakob disease and the acquired and transmissible spongiform encephalopathies. Clin Infect Dis 2004; 38: 697-704
14. Will RG. Epidemiology of Creutzfeldt-Jakob disease. Br Med Bull 1993; 49: 960-70
15. Beghi E, Gandolfo C, Ferrarese C, et al. Bovine spongiform encephalopathy and Creutzfeldt-Jakob disease: facts and uncertainties underlying the causal link between animal and human diseases. Neurol Sci 2004; 25 (3): 122-9
16. Scott MR, Will R, Ironside J, et al. Compelling transgenetic evidence for transmission of bovine spongiform encephalopathy prions to humans. Proc Natl Acad Sci U S A 1999; 96: 15137-42
17. Lasmezas CI, Deslys JP, Demaimay R, et al. BSE transmission to macaques. Nature 1996; 381: 743-4
18. Cousens SN, Zeidler M, Esmonde TF, et al. Sporadic Creutzfeldt-Jakob disease in the United Kingdom: analysis of epidemiological surveillance data for 1970-96. BMJ 1997; 315: 389-95
19. National CJD Surveillance Unit. Creutzfeldt-Jakob disease surveillance in the UK. Tenth annual report 2001 [online]. Available from URL: http://www.cjd.ed.ac.uk/rep2001.html [Accessed 2005 May 15]
20. Coehn CH. Does improvement in case ascertainment explain the increase in sporadic Creutzfeldt-Jakob disease since 1970 in the United Kingdom? Am J Epidemiol 2000; 152: 474-9
21. Capek I, Vaillant V. Creutzfeldt-Jakob disease and related diseases in France from 1998 to 2000. Euro Surveill 2003; 8: 14-9
22. Glatzel M, Rogivue C, Ghani A, et al. A Incidence of Creutzfeldt-Jakob disease in Switzerland. Lancet 2002; 360: 139-41
23. National CJD Surveillance Unit. Creutzfeldt-Jakob disease surveillance in the UK: CJD statistics [online]. Available from URL: http://www.cjd.ed.ac.uk/ eleventh/figures.htm [Accessed 2005 Dec 2]
24. National CJD Surveillance Unit. Creutzfeldt-Jakob disease surveillance in the UK. 2003. Eleventh annual report 2002 [online]. Available from URL: http://www.cjd.ed.ac.uk/eleventh/rep2002.htm [Accessed 2005 May 15]
25. Cousens S, Smith PG, Ward H, et al. Geographical distribution of variant Creutzfeldt-Jakob disease in Great Britain, 1994-2000. Lancet 2001; 357: 1002-7
26. Bryant G, Monk P. Final report of the investigation into the North Leicestershire cluster of variant Creutzfeldt-Jakob. 2001 [online]. Available from URL: http://www.leics-ha.org.uk [Accessed 2005 May 15]
27. Alperovitch A, Zerr I, Pocchiari M, et al. Codon 129 prion protein genotype and sporadic Creutzfeldt-Jakob disease. Lancet 1999; 353: 1673-4
28. Jackson GS, Beck JA, Navarrete C, et al. HLA-DQ7 antigen and resistance to variant CJD. Nature 2001; 414: 269-70
29. Pepys MB, Bybee A, Booth DR, et al. MHC typing in variant Creutzfeldt-Jakob disease. Lancet 2003; 361: 487-9
30. Laplanche JL, Lepage V, Peoc'h K, et al. HLA in French patients with variant Creutzfeldt-Jakob disease. Lancet 2003; 361: 531-2
31. Aylin P, Bunting J, De Stavola B, et al. Mortality from dementia in occupations at risk of exposure to bovine spongiform encephalopathy: analysis of death registrations. BMJ 1999; 318: 1044-5
32. Collins S, Law MG, Fletcher A, et al. Surgical treatment and risk of sporadic Creutzfeldt-Jakob disease: a case-control study. Lancet 1999; 353: 693-7
33. Van Duijn CM, Delasnerie-Lauprêtre N, Fasullo C, et al. Case-control study of risk factors of Creutzfeldt-Jakob disease Europe during 1993-1995. Lancet 1998; 351: 1081-5
34. Wientjens D, Davanipour Z, Hofman A, et al. Risk factors Creutzfeldt-Jakob disease: a re-analysis of case-control studies. Neurology 1996; 46: 1287-91
35. Houston F, Foster JD, Chong A, et al. Transmission of BSE by blood transfusion in sheep. Lancet 2000; 356: 999-1000
36. Hunter N, Foster J, Chong A, et al. Transmission of prion diseases by blood transfusion. J Gen Virol 2002; 83: 2897-905
37. Herzog C, Salès N, Etchegaray N, et al. Tissue distribution of bovine spongiform encephalopathy agent in primates after intravenous or oral infection. Lancet 2004; 363: 422-8
38. Wilson K, Code C, Ricketts MN. Risk of acquiring Creutzfeldt-Jakob disease from blood transfusions: systematic review of case-control studies. BMJ 2000; 321: 17-9
39. Peden AH, Head MW, Ritchie DL, et al. Preclinical vCJD after blood transfusion in a PRNP codon 120 heterozygous patient. Lancet 2004; 264: 527-9
40. Alperovitch A, Zerr I, Pochiari M, et al. Codon 129 prion protein genotype and sporadic Creutzfeldt-Jakob disease. Lancet 1999; 353: 1673-4
41. Llewelyn CA, Hewitt PE, Knight RS, et al. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet 2004; 363: 417-21
42. Andrews NJ, Farrington CP, Ward HJ, et al. Deaths from variant Creutzfeldt-Jakob disease in the UK. Lancet 2003; 361: 751-2
43. Andrews NJ. Quarterly report. Incidence of variant Creutzfeldt-Jakob Disease onset and deaths in the UK (updated 23rd April 2004) [online]. Available from URL: http://www.cjd.ed.ac.uk/vcjdq.htm [Accessed 2005 May 15]
44. Cousens SN, Vynnycky E, Zeidler M, et al. Predicting the CJD epidemic in humans. Nature 1997; 385: 197-8
45. Ghani AC, Ferguson NM, Donnelly CA, et al. Predicted vCJD mortality in Great Britain. Nature 2000; 406: 583-4
46. Ghani AC, Donnelly CA, Ferguson NM, et al. Updated projections of future vCJD deaths in the UK. BMC Infect Dis 2003; 3: 1-4
47. Hilton DA, Ghani AC, Conyers L, et al. Prevalence of lymphoreticular prion protein accumulation in UK tissue samples. J Pathol 2004; 203: 733-9
48. Kimberlin RH, Walker CA. Pathogenesis of mouse scrapie: dynamics of agent replication in spleen, spinal cord and brain after infection by different routes. J Comp Pathol 1979; 89: 551-62
49. Clarke MC, Haig DA. Multiplication of scrapie agent in mouse spleen. Res Vet Sci 1971; 12: 195-7
50. Fraser H, Dickinson AG. Pathogenesis of scrapie in the mouse: the role of the spleen. Nature 1970; 226: 462-3
51. Fraser H, Dickinson AG. Studies of the lymphoreticular system in the pathogenesis of scrapie: the role of the spleen and thymus. J Comp Pathol 1978; 88: 563-73
52. Baldauf E, Beekes M, Diringer H. Evidence for an alternative direct route of access for the scrapie agent to the brain bypassing the spinal cord. J Gen Virol 1997; 78: 1187-97
53. Beekes M, Baldauf E, Diringer H. Sequential appearance and accumulation of pathognomonic markers in the central nervous system of hamsters orally infected with scrapie. J Gen Virol 1996; 77: 1925-34
54. Kimberlin RH, Walker CA. Pathogenesis of scrapie in mice after intragastric infection. Virus Res 1989; 12: 213-20
55. Beekes M, McBride PA. Early accumulation of pathological PrP in the enteric nervous system and gut-associated lymphoid tissue of hamsters orally infected with scrapie. Neurosci Lett 2000; 278: 181-4
56. Maignien T, Lasmézas CI, Beringue V, et al. Pathogenesis of the oral route of infection of mice with scrapie and bovine spongiform encephalopathy agents. J Gen Virol 1999; 80: 3035-42
57. Andréoletti O, Berthon P, Marc D, et al. Early accumulation of PrPsc in gut-associated lymphoid and nervous tissues of susceptible sheep from a Romanov flock with natural scrapie. J Gen Virol 2000; 81: 3115-26
58. Van Keulen L, Schreuder EC, Vromans MEW, et al. Pathogenesis of natural scrapie in sheep. Arch Virol 2000; 16: 57-71
59. McBride P, Schulz-Schaeffer WJ, Donaldson M, et al. Early spread of scrapie from the gastrointestinal tract to the central nervous system involves autonomic fibers of the splanchnic and vagus nerves. J Gen Virol 2001; 75: 9320-7
60. Kimberlin RH, Hall SM, Walker CA. Pathogenesis of mouse scrapie: evidence for direct neural spread of infection to the CNS after injection of sciatic nerve. J Neurol Sci 1983; 61: 315-25
61. Fraser H, Brown KL, Stewart K, et al. Replication of scrapie in spleen of SCID mice follows reconstitution with wild-type mouse bone-marrow. J Gen Virol 1996; 77: 1935-40
62. Kimberlin RH, Walker CA. Incubation period in six models of intraperitoneally injected scrapie depend mainly on the dynamics of agent replication within the nervous system and not the lymphoreticular system. J Gen Virol 1988; 69: 2953-60
63. Lasmezas CI, Cesbron JY, Deslys JP, et al. Immune system-dependent and independent replication of the scrapie agent. J Virol 1996; 70: 1292-5
64. Schreuder BEC, Van Keulen L, Vromans MEW, et al. Tonsillar biopsy and PrPsc detection in the preclinical diagnosis of scrapie. Vet Rec 1998; 142: 564-8
65. Jeffrey M, Begara-McGorum I, Clark S, et al. Occurrence and distribution of infection-specific PrP in tissues of clinical scrapie cases and cull sheep from scrapie-affected farms in Shetland. J Comp Pathol 2002; 127: 264-73
66. Jeffrey M, Ryder S, Martin S, et al. Oral inoculation of sheep with the agent of bovine spongiform encephalopathy (BSE): 1. Onset and istribution of disease-specific PrP accumulation in brain and viscera. J Comp Pathol 2001; 124: 280-9
67. Wells GAH, Hawkins SAC, Green RB, et al. Preliminary observations on the pathogenesis of experimental bovine spongi-form encephalopathy (BSE): an update. Vet Rec 1998; 142: 103-6
68. Wells GA, Spiropoulos J, Hawkins SA, et al. Pathogenesis of experimental bovine spongiform encephalopathy: preclinical infectivity in tonsil and observations on the distribution of lingual tonsil in slaughtered cattle. Vet Rec 2005; 156: 401-7
69. Foster JD, Parnham DW, Hunter N, et al. Distribution of the prion protein in sheep terminally affected with BSE following experimental oral transmission. J Gen Virol 2001; 82: 2319-26
70. Bruce ME, McConnell I, Will RG, et al. Detection of variant Creutzfeldt-Jakob disease infectivity in extraneural tissues. Lancet 2001; 358: 208-9
71. Hill AF, Zeidler M, Ironside JW, et al. Diagnosis of new variant Creutzfeldt-Jakob disease by tonsil biopsy. Lancet 1997; 349: 99-100
72. Wadsworth JDF, Joiner S, Hill AF, et al. Tissue distribution of protease resistant prion protein in variant Creutzfeldt-Jakob disease using a highly sensitive immunoblotting assay. Lancet 2001; 358: 171-80
73. Hill AF, Butterworth RJ, Joiner S. Investigation of variant Creutzfeldt-Jakob disease and other human prion diseases with tonsil biopsy samples. Lancet 1999; 353: 183-9
74. Jeffrey M, Martin S, Thomson JR, et al. Onset and distribution of tissue PrP: accumulation in scrapie-affected Suffolk sheep as demonstrated by sequential necropsies and tonsillar biopsies. J Comp Pathol 2001; 125: 48-57
75. Race R, Oldstone M, Chesebro B. Entry versus blockade of brain infection following oral or intraperitoneal scrapie administration: role of prion protein expression in peripheral nerves and spleen. J Virol 2000; 74: 828-33
76. Brown P, Rohwer RG, Dunstan BC, et al. The distribution of infectivity in blood components and plasma derivatives in experimental models of transmissible spongiform encephalopathy. Transfusion 1998; 38: 810-6
77. Blattler T, Brandner S, Raeber AJ, et al. PrP-expressing tissue required for transfer of scrapie infectivity from spleen to brain. Nature 1997; 389: 69-73
78. Shlomchik MJ, Radebold K, Duclos N, et al. Neuroinvasion by a Creutzfeldt-Jakob disease agent in the absence of B cells and follicular dendritic cells. Proc Natl Acad Sci U S A 2001; 98: 9289-94
79. Klein MA, Frigg R, Flechsig E, et al. A crucial role for B cells in neuroinvasive scrapie. Nature 1997; 390: 687-90
80. Klein MA, Frigg R, Raeber AJ, et al. PrP expression in B lymphocytes is not required for prion neuroinvasion. Nat Med 1998; 4: 1429-33
81. Jeffrey M, McGovern G, Goodsir GM, et al. Sites of prion protein accumulation in scrapie-infected mouse spleen revealed by immuno-electron microscopy. J Pathol 2000; 191: 323-32
82. Heggebo R, Press C, Gunnes G, et al. Distribution and accumulation of PrP in gut-associated and peripheral lymphoid tissue of scrapie-affected Suffolk sheep. J Gen Virol 2002; 83: 479-89
83. Fraser H, Farquhar CF. Ionising radiation has no influence on scrapie incubation period in mice. Vet Microbiol 1987; 13: 211-23
84. O'Rourke KI, Huff TP, Leathers CW, et al. SCID mouse spleen does not support scrapie agent replication. J Gen Virol 1994; 75: 1511-4
85. Brown P, Stewart K, Ritchie DL, et al. Scrapie replication in lymphoid tissues depends on prion protein-expressing follicular dendritic cells. Nat Med 1999; 11: 1308-12
86. Montrasio F, Frigg R, Glatzel M, et al. Impaired prion replication in spleens of mice lacking functional follicular dendritic cells. Science 2000; 288: 1257-9
87. Kaeser PS, Klein MA, Schwarz P, et al. Efficient lymphoreticular prion propagation requires PrPc in stromal and hematopoietic cells. J Virol 2001; 75: 7097-106
88. Manuelidis L, Zaitsev I, Koni P, et al. Follicular dendritic cells and dissemination of Creutzfeldt-Jakob disease. J Virol 2000; 74: 8614-22
89. Klein MA, Kaeser PS, Schwarz P, et al. Complement facilitates early prion pathogenesis. Nat Med 2001; 7: 488-92
90. Mabbott NA, Bruce ME, Botto M, et al. Temporary depletion of complement component C3 or genetic deficiency of C1q significantly delays onset of scrapie. Nat Med 2001; 7: 485-7
91. Raeber AJ, Klein MA, Frigg R, et al. PrP-dependent association of prions with splenic but not circulating lymphocytes of scrapie-infected mice. EMBO J 1999; 18: 2702-6
92. Bruce ME, Brown KL, Mabbott NA, et al. Follicular dendritic cells in TSE pathogenesis. Immunol Today 2000; 9: 442-6
93. Aucouturier P, Geissmann F, Damotte D, et al. Infected splenic dendritic cells are sufficient for prion transmission to the CNS in mouse scrapie. J Clin Invest 2001; 108: 703-8
94. Aguzzi A. Peripheral prion pursuit. J Clin Invest 2001; 108: 661-2
95. Felten DL, Felten SY, Carlson SL, et al. Noradrenergic and peptidergic innervation of lymphoid tissue. J Immunol 1989; 135: 755-65
96. Heggebo R, Gonzalez L, Press C, et al. Disease-associated PrP in the enteric nervous system of scrapie-affected Suffolk sheep. J Gen Virol 2003; 84: 1327-38
97. Glatzel M, Aguzzi A. PrPc expression in the peripheral nervous system is a determinant of prion neuroinvasion. J Gen Virol 2000; 81: 2813-21
98. McEwen BS, Grafstein B. Fast and slow components in axonal transport of protein. J Cell Biol 1968; 38: 494-508
99. Dormont D. Prion diseases: pathogenesis and public health concerns. FEBS Lett 2002; 529: 17-21
100. Brandner S, Raeber A, Saller A, et al. Normal host prion protein (PrPc) is required for scrapie spread within the central nervous system. Proc Natl Acad Sci U S A 1996; 93: 13148-51
101. Follett J, Lemaire-Vieille C, Blanquet-Grossard F, et al. PrP expression and replication by Schwann cells: implications in prion spreading. J Virol 2002; 76: 2434-9
102. Hegde RS, Tremblay P, Groth D, et al. Transmissible and genetic prion diseases share a common pathway of neurodegeneration. Nature 1999; 402: 822-6
103. Chiesa R, Piccardo P, Quaglio E, et al. Molecular distinction between pathogenic and infectious properties of the prion protein. J Virol 2003; 77: 7611-22
104. Soto C, Saborio G. Prions: disease propagation and disease therapy by conformational transmission. Trends Mol Med 2001; 7: 109-14
105. Forloni G, Vari M, Colombo L, et al. Prion diseases: time for a therapy? Curr Med Chem - Immun Endoc Metab Agents 2003; 3: 185-97
106. Ladogana A, Casaccia P, Ingrosso L, et al. Sulphate polyanions prolong the incubation period of scrapie-infected hamsters. J Gen Virol 1992; 73: 661-5
107. Ehlers B, Diringer H. Dextran sulfate 500 delays and prevents mouse scrapie by impairment of agent replication in spleen. J Gen Virol 1984; 65: 1325-30
108. Adjou KT, Deslys JP, Demaimay R, et al. Probing the dynamics of prion diseases with amphotericin B. Trends Microbiol 1997; 5: 27-31
109. Priola SA, Raines A, Caughey WS. Porphyrin and phthalocyanine antiscrapie compounds. Science 2000; 287: 1503-6
110. Caughey WS, Raimond LD, Horiachi M, et al. Inhibition of protease-resistant prion protein formation by porphyrins and phtalocyamines. Proc Natl Acad Sci U S A 1998; 95: 12117-22
111. Supattapone S, Wille H, Uyechi L, et al. Branched polyamines cure prion infected neuroblastoma cells. J Virol 2001; 75: 3453-61
112. Korth C, May BC, Cohen FE, et al. Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. Proc Natl Acad Sci U S A 2001; 98: 9836-41
113. Doh-ura K, Iwaki T, Caughey B. Lysomotropic agents and cysteine protease inhibitors inhibit scrapie-associated prion protein accumulation. J Virol 2000; 74: 4894-7
114. Collins SJ, Lewis V, Brazier M, et al. Quinacrine does not prolong survival in a murine Creutzfeldt-Jakob disease model. Ann Neurol 2002; 52: 503-6
115. Barret A, Tagliavini F, Forloni G, et al. Evaluation of quinacrine treatment for prion diseases. J Virol 2003; 77: 8462-9
116. Brown P. Drug therapy in human and experimental transmissible spongiform encephalopathy. Neurology 2002; 56: 1720-5
117. Follette P. Prion disease treatment's early promise unravels. Science 2003; 299: 191-2
118. Furukawa H, Takahashi M, Nakajima M, et al. Prospects of the therapeutic approaches to Creutzfeldt-Jakob disease: a clinical trial of antimalarial, quinacrine. Nippon Rinsho 2002; 60: 1649-57
119. Merlini G, Ascari E, Amboldi N, et al. Interaction of the anthracycline 4′-iodo-4′-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis. Proc Natl Acad Sci U S A 1995; 92: 2959-63
120. Gianni L, Belotti V, Gianni AM, et al. New drug therapy of amyloidoses: resorption of AL-type deposits with 4′-iodo-4′-deoxydoxorubicin. Blood 1995; 86: 855-61
121. Tagliavini F, McArthur RA, Canciani B, et al. Effectiveness of anthracycline against experimental prion disease in Syrian hamsters. Science 1997; 276: 1119-22
122. Mitscher LA. The chemistry of the tetracycline antibiotics. New York: Marcel Dekker, 1978
123. Tagliavini F, Forloni G, Colombo L, et al. Tetracycline affects abnormal properties of synthetic PrP peptides and PrP(Sc) in vitro. J Mol Biol 2000; 300: 1309-22
124. Forloni G, Jussich S, Awan T, et al. Tetracyclines affect prion infectivity. Proc Natl Acad Sci U S A 2002; 99: 10849-53
125. Weiner HL, Selkoe D. Inflammation and therapeutic vaccination in CNS diseases. Nature 2002; 420: 879-84
126. Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999; 400: 173-7
127. Hock C, Konietzko U, Streffer JR, et al. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron 2003; 38: 547-54
128. Gabizon R, McKinley MP, Groth D, et al. Immunoaffinity purification and neutralization of scrapie prion infectivity. Proc Natl Acad Sci U S A 1988; 85: 6617-21
129. Enari M, Flechsig E, Weissman C. Scrapie prion protein accumulation by scrapie-infected neuroblastoma cells abrogated by 'exposure' to 'a 'prion' protein antibody. Proc Natl Acad Sci U S A 2001; 98: 9295-9
130. Peretz D, Williamson RA, Kaneko K, et al. Antibodies inhibits prion propagation and clear cell cultures of prion infectivity. Nature 2001; 412: 739-43